Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ditchdigger who wrote (14232)	1/5/2006 6:10:36 PM
From: Sergio H	Respond to of 23958

Hi Ditch. Nice pick. A few posts on SI on CSFB's target price change on VRTX. Here's one: Message 22030760 Recent notes from Goldman Sach's: <VRTX (IL/N): Upgrading VRTX to IL/N based on key expected 2006 data December 14, 2005 Based on defining Phase II data expected in 2006 on Vertexs lead candidate VX-950 for hepatitis C as well as Phase II data on oral inflammatory agent VX-702, we are upgrading our rating on Vertex to In-Line from Underperform in the context of our Neutral coverage view. Despite the strong YTD performance of VRTX (+150%), and potential for short-term pullback if there are even minor clinical setbacks or delays, we believe there is further upside to VRTX stock over 2006 if Phase II candidates are successful. Further, we note that the rest of the pipeline, though early-stage, is steadily and strategically expanding and bolstered by collaborations, including those with Merck (cancer), Glaxo (newly established pain program, and historical AIDS program through which Vertex already earns royalties), and Novartis. The main risk would be clinical setbacks or delays.